NEM:ASXNewmont Corporation Registered Shs Chess Depositary Interests Repr 1 Sh Analysis
Data as of 2026-06-19 - not real-time
A$146.52
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Newmont (NEM.AX) is trading at AUD 146.52, slightly below its 20‑day SMA of 148.68 and well under its 30‑day DCF fair value of 333.78, implying a potential upside of over 30% to the nearest resistance at 158.80. Technical signals are mixed but leaning bullish: the MACD histogram is positive (0.86) with a bullish crossover, while the RSI sits at a neutral 46.9, suggesting room for a modest rally. The stock benefits from a strong fundamentals backdrop – revenue surged 45.8% YoY, operating margins sit at an impressive 61%, and ROE is 25.8%, all supported by low leverage (debt‑to‑equity ~15%) and robust free cash flow. Dividend sustainability appears solid, with a modest 0.95% yield and a payout ratio of just 13%, underscoring the company’s capacity to maintain shareholder returns.
The broader environment adds both opportunities and cautions: gold’s safe‑haven appeal underpins demand, yet the sector’s commodity exposure and Newmont’s geographically diverse operations introduce medium‑level regulatory and geopolitical risk. Volatility is elevated at 53% over the past 30 days, and beta near 0.88 indicates the stock moves somewhat less than the market. Recent leadership appointments (new CFO, COO, and CTO) may further strengthen execution, and analysts collectively rate the stock as a “buy” with a mean target of AUD 192.7, reinforcing the case for a medium‑to‑long‑term position.
The broader environment adds both opportunities and cautions: gold’s safe‑haven appeal underpins demand, yet the sector’s commodity exposure and Newmont’s geographically diverse operations introduce medium‑level regulatory and geopolitical risk. Volatility is elevated at 53% over the past 30 days, and beta near 0.88 indicates the stock moves somewhat less than the market. Recent leadership appointments (new CFO, COO, and CTO) may further strengthen execution, and analysts collectively rate the stock as a “buy” with a mean target of AUD 192.7, reinforcing the case for a medium‑to‑long‑term position.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish MACD histogram with positive momentum
- Price near support at 129.6 and below short‑term SMA
- Stable volume and recent executive appointments
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong revenue growth (45.8%) and high operating margins (61%)
- Low leverage and ample free cash flow supporting dividend
- Significant valuation gap to DCF fair value (+31% upside)
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Sustained gold demand and defensive sector characteristics
- Robust ROE (25.8%) and consistent cash generation
- Undervalued relative to intrinsic value with long‑run upside
Key Metrics & Analysis
Financial Health
Revenue Growth45.80%
Profit Margin33.87%
P/E Ratio13.4
ROE25.83%
ROA14.89%
Debt/Equity15.76
P/B Ratio3.2
Op. Cash FlowA$12.1B
Free Cash FlowA$9.8B
Technical Analysis
TrendNeutral
RSI46.9
SupportA$129.63
ResistanceA$158.80
MA 20A$148.68
MA 50A$154.24
MA 200A$149.01
MACDBullish
VolumeStable
Fear & Greed Index92.14
Valuation
Fair ValueA$333.78
Target PriceA$192.71
Upside/Downside31.53%
GradeUndervalued
TypeBlend
Dividend Yield0.95%
Risk Assessment
Beta0.88
Volatility53.29%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.